{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:38:39Z","timestamp":1784547519330,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vincristine-induced peripheral neuropathy (VIPN) is an adverse effect of regimens used for the treatment of aggressive B-cell non-Hodgkin lymphoma (B-NHL). A single-nucleotide polymorphism (SNP) in the promotor region of the <jats:italic>CEP72<\/jats:italic> gene has been identified as risk factor for the development of VIPN in children. To validate these results in adults we aimed to determine the association of the high-risk <jats:italic>CEP72<\/jats:italic> (rs924607 TT genotype) with the occurrence and severity of VIPN. Analysis of SNP rs924607 (TT, CC or CT) was performed in all enrolled patients with available blood samples with a TaqMan genotyping assay. Rates and grades of VIPN were assessed prospectively as part of the RICOVER-60 trial. <jats:italic>CEP72<\/jats:italic> genotype could be assessed in 519 patients. VIPN data was available for 499\/519 patients who were included in the final analysis. 286 (57%) patients developed VIPN of any grade during treatment. Grade 2\u20134 VIPN occurred in 33% (166\/499) of patients. The high-risk <jats:italic>CEP72<\/jats:italic> TT genotype at rs924607 was identified in 97\/499 (19%) patients. The TT genotype was not correlated with VIPN in the overall study population compared to patients with either CC or CT genotypes (<jats:italic>p<\/jats:italic>\u2009=\u20090.748). However, in the subgroup of female patients, the TT genotype was associated with increased occurrence of any-grade VIPN as well as grade 2\u20134 VIPN as compared to patients with either CC or CT genotypes (<jats:italic>p<\/jats:italic>\u2009=\u20090.016 and <jats:italic>p<\/jats:italic>\u2009=\u20090.020, respectively). Thus, the SNP rs924607 in the <jats:italic>CEP72<\/jats:italic> gene is associated with increased VIPN incidence in female patients with aggressive B-NHL treated with CHOP chemotherapy. Trial registration ClinicalTrials.gov identifier: NCT00052936, submission date: 2005-06-23, EudraCT Number: 2010-019587-36.<\/jats:p>","DOI":"10.1007\/s00277-024-05973-9","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:35:12Z","timestamp":1725420912000},"page":"4599-4606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Konstantinos","family":"Christofyllakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Kaddu-Mulindwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Lesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Rixecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Age","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Regitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg Thomas","family":"Bittenbring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Thurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Poeschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Ziepert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Bewarder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"5973_CR1","doi-asserted-by":"crossref","unstructured":"Swerdlow SH et al The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol. 127, no. 20. American Society of Hematology, pp. 2375\u20132390, May-2016","DOI":"10.1182\/blood-2016-01-643569"},{"key":"5973_CR2","doi-asserted-by":"crossref","unstructured":"Armitage JO (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma, Blood, vol. 89, no. 11, pp. 3909\u20133918, Jun","DOI":"10.1182\/blood.V89.11.3909"},{"key":"5973_CR3","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M et al (May 2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol 7(5):379\u2013391","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"5973_CR4","doi-asserted-by":"crossref","unstructured":"Coiffier B et al (2002) Jan., CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, N. Engl. J. Med., vol. 346, no. 4, pp. 235\u2013242","DOI":"10.1056\/NEJMoa011795"},{"key":"5973_CR5","doi-asserted-by":"crossref","unstructured":"Coiffier B et al (2010) Sep., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte, Blood, vol. 116, no. 12, pp. 2040\u20132045","DOI":"10.1182\/blood-2010-03-276246"},{"key":"5973_CR6","unstructured":"Tilly H et al (2021) Dec., Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma, N. Engl. J. Med., vol. 386, no. 4, pp. 351\u2013363"},{"key":"5973_CR7","doi-asserted-by":"crossref","unstructured":"Poeschel V et al (2019) Dec., Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial, Lancet, vol. 394, no. 10216, pp. 2271\u20132281","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"5973_CR8","doi-asserted-by":"crossref","unstructured":"Ohmachi K et al (2011) Jun., Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., vol. 22, no. 6, pp. 1382\u20131391","DOI":"10.1093\/annonc\/mdq619"},{"key":"5973_CR9","doi-asserted-by":"crossref","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: A current review, Ann. Neurol., vol. 81, no. 6, pp. 772\u2013781, Jun","DOI":"10.1002\/ana.24951"},{"issue":"11","key":"5973_CR10","first-page":"2416","volume":"6","author":"E Mora","year":"2016","unstructured":"Mora E, Lavoie Smith EM, Donohoe C, Hertz DL (2016) Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res 6(11):2416","journal-title":"Am J Cancer Res"},{"key":"5973_CR11","doi-asserted-by":"crossref","unstructured":"van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH (Jun. 2017) Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol \/ Hematol 114:114\u2013130","DOI":"10.1016\/j.critrevonc.2017.04.004"},{"issue":"2","key":"5973_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0022-510X(70)90013-4","volume":"10","author":"WG Bradley","year":"1970","unstructured":"Bradley WG, Lassman LP, Pearce GW, Walton JN (1970) The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 10(2):107\u2013131","journal-title":"J Neurol Sci"},{"issue":"4","key":"5973_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253\u2013265","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"5973_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bcp.13126","volume":"83","author":"D Bates","year":"2017","unstructured":"Bates D, Eastman A (2017) Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 83(2):255\u2013268","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"5973_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF03259853","volume":"1","author":"SS Legha","year":"1986","unstructured":"Legha SS (1986) Vincristine Neurotoxicity: pathophysiology and management. Med Toxicol 1(6):421\u2013427","journal-title":"Med Toxicol"},{"key":"5973_CR16","doi-asserted-by":"crossref","unstructured":"Renbarger JL, McCammack KC, Rouse CE, Hall SD (2008) Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients, Pediatr. Blood Cancer, vol. 50, no. 4, pp. 769\u2013771, Apr","DOI":"10.1002\/pbc.21435"},{"key":"5973_CR17","doi-asserted-by":"crossref","unstructured":"Bewarder M et al Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP, Haematologica, vol. 108, no. 10. Haematologica, pp. 2844\u20132849, Feb-2023","DOI":"10.3324\/haematol.2022.282126"},{"key":"5973_CR18","doi-asserted-by":"crossref","unstructured":"Fradkin M et al (2019) Jan., Management of peripheral neuropathy induced by chemotherapy., Curr. Med. Chem., vol. 26, no. 25, pp. 4698\u20134708","DOI":"10.2174\/0929867326666190107163756"},{"key":"5973_CR19","unstructured":"Diouf B et al (2015) Feb., Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia, JAMA, vol. 313, no. 8, pp. 815\u2013823"},{"key":"5973_CR20","doi-asserted-by":"crossref","unstructured":"Stock W et al (2017) Mar., An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia, Clin. Pharmacol. Ther., vol. 101, no. 3, pp. 391\u2013395","DOI":"10.1002\/cpt.506"},{"key":"5973_CR21","doi-asserted-by":"crossref","unstructured":"Zgheib NK et al (Aug. 2018) Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics 28(8):189\u2013195","DOI":"10.1097\/FPC.0000000000000345"},{"issue":"2","key":"5973_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","volume":"26","author":"A Gutierrez-Camino","year":"2016","unstructured":"Gutierrez-Camino A et al (2016) Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics 26(2):100\u2013102","journal-title":"Pharmacogenet Genomics"},{"key":"5973_CR23","doi-asserted-by":"crossref","unstructured":"Wright GEB et al (2019) Feb., Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes, Clin. Pharmacol. Ther., vol. 105, no. 2, pp. 402\u2013410","DOI":"10.1002\/cpt.1179"},{"key":"5973_CR24","doi-asserted-by":"crossref","unstructured":"Sawaki A et al (2020) Jan., Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy., Int. J. Hematol., vol. 111, no. 5, pp. 686\u2013691","DOI":"10.1007\/s12185-020-02832-x"},{"key":"5973_CR25","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M et al (Feb. 2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u2009+\u2009B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"5973_CR26","doi-asserted-by":"crossref","unstructured":"Iguchi N, Hecht SL, Gao D, Wilcox DT, Malykhina AP, Cost NG (2022) Sexual dimorphic impacts of systemic vincristine on lower urinary tract function, Sci. Reports 2022 121, vol. 12, no. 1, pp. 1\u201315, Mar","DOI":"10.1038\/s41598-022-08585-3"},{"key":"5973_CR27","doi-asserted-by":"crossref","unstructured":"Kai K et al (2006) Apr., Species and Sex Differences in Susceptibility to Olfactory Lesions Among the Mouse, Rat and Monkey Following an Intravenous Injection of Vincristine Sulphate, http:\/\/dx.doi.org\/10.1080\/01926230600695557, vol. 34, no. 3, pp. 223\u2013231","DOI":"10.1080\/01926230600695557"},{"key":"5973_CR28","doi-asserted-by":"crossref","unstructured":"Joseph EK, Levine JD (2003) Sexual dimorphism for protein kinase c\u03b5 signaling in a rat model of vincristine-induced painful peripheral neuropathy, Neuroscience, vol. 119, no. 3, pp. 831\u2013838, Jul","DOI":"10.1016\/S0306-4522(03)00203-3"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05973-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:29:13Z","timestamp":1730712553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05973-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5973"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05973-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the respective local ethical review committees in Germany, Czech Republic, and Switzerland for each participating center. The study was performed in accordance with the rules of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Written informed consent was obtained from all patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}